Characterization of HIV-1 subtypes and transmitted drug resistance among treatment-naive HIV-infected individuals in Zhejiang, China, 2014-2017

  • Yufan Xu
  • Xiaorong Peng
  • Xiuming Peng
  • Shujing Ji
  • Bin Chen
  • Liyan Wang
  • Xiangyun Lu
  • Tiansheng Xie
  • Tao Sun
  • Hui Wang
  • Nanping Wu
Brief Report
  • 33 Downloads

Abstract

In recent years, transmitted drug resistance (TDR) has adversely impacted upon first-line therapy for HIV-infected individuals. To understand the current subtype distribution and TDR level in Zhejiang, China we performed phylogenetic analysis and genotypic drug resistance testing of treatment-naive HIV-infected individuals. A total of 153 HIV-1 Pol genes were successfully amplified. The distribution of HIV-1 genotypes was as follows: CRF01_AE (43.8%); CRF07_BC (37.9%); subtype B/B’ (7.2%); CRF08_BC (5.2%); and others (5.9%). Drug resistance analysis demonstrated that 11.1% of isolates contained at least one NRTI or NNRTI resistance-associated mutations while 2.0% were identified to be resistant to PIs. These findings enhance our understanding of the genetic diversity of HIV-1 strains circulating in Zhejiang and provide some guidelines for HIV initial treatment therapy.

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the Institutional Ethics Committee of The First Affiliated Hospital, Medical College of Zhejiang University, China.

Informed consent

Signed informed consent was obtained from each patient before sample collection in this study.

Supplementary material

705_2018_3839_MOESM1_ESM.doc (438 kb)
Supplementary material 1 (DOC 438 kb)
705_2018_3839_MOESM2_ESM.doc (66 kb)
Supplementary material 2 (DOC 65 kb)

References

  1. 1.
    Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ (2001) Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 135:17–26CrossRefPubMedGoogle Scholar
  2. 2.
    Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO (2002) Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288:181–188CrossRefPubMedGoogle Scholar
  3. 3.
    Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD (2008) Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 47:266–285CrossRefPubMedGoogle Scholar
  4. 4.
    Taiwo B (2009) Understanding transmitted HIV resistance through the experience in the USA. Int J Infect Dis 13:552–559CrossRefPubMedGoogle Scholar
  5. 5.
    Avila-Rios S, Sued O, Rhee SY, Shafer RW, Reyes-Teran G, Ravasi G (2016) Surveillance of HIV transmitted drug resistance in Latin America and the Caribbean: a systematic review and meta-analysis. PLoS One 11:e0158560CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sui H, Gui T, Jia L, Guo W, Han J, Liu Y, Bao Z, Li H, Li J, Li L (2014) Different frequencies of drug resistance mutations among HIV-1 subtypes circulating in China: a comprehensive study. PLoS One 9:e91803CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Li X, Li W, Zhong P, Fang K, Zhu K, Musa TH, Song Y, Du G, Gao R, Guo Y, Yan W, Xuan Y, Wei P (2016) Nationwide trends in molecular epidemiology of HIV-1 in China. AIDS Res Hum Retrovir 32:851–859CrossRefPubMedGoogle Scholar
  8. 8.
    Wu J, Meng Z, Xu J, Lei Y, Jin L, Zhong P, Han R, Su B (2013) New emerging recombinant HIV-1 strains and close transmission linkage of HIV-1 strains in the Chinese MSM population indicate a new epidemic risk. PLoS One 8:e54322CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chen L, Pan X, Ma Q, Yang J, Xu Y, Zheng J, Wang H, Zhou X, Jiang T, Jiang J, He L, Jiang J (2017) HIV cause-specific deaths, mortality, risk factors, and the combined influence of HAART and late diagnosis in Zhejiang, China, 2006-2013. Sci Rep 7:42366CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zhao B, Han X, Xu J, Hu Q, Chu Z, Zhang J, Lu L, Wang Z, Fu J, Chen X, Yan H, Zhuang M, Wang L, Sun A, Zhang CM, Shang H (2015) Increase of RT-related transmitted drug resistance in non-CRF01_AE among HIV type 1-infected men who have sex with men in the 7 cities of China. J Acquir Immune Defic Syndr 68:250–255CrossRefPubMedGoogle Scholar
  11. 11.
    Yao Y, Xin R, Yang J, Xu Y, Zhang J, Xia Y, Pan X, Guo Z, Song Y (2015) Trends of subtype variation of human immunodeficiency virus type 1 in Zhejiang Province, China. Virus Genes 50:22–28CrossRefPubMedGoogle Scholar
  12. 12.
    Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347:385–394CrossRefPubMedGoogle Scholar
  13. 13.
    Lai CC, Hung CC, Chen MY, Sun HY, Lu CL, Tseng YT, Chang SF, Su YC, Liu WC, Hsieh CY, Wu PY, Chang SY, Chang SC (2012) Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan. J Antimicrob Chemother 67:1254–1260CrossRefPubMedGoogle Scholar
  14. 14.
    Li JF, Linley L, Kline R, Ziebell R, Heneine W, Johnson JA (2016) Sensitive sentinel mutation screening reveals differential underestimation of transmitted HIV drug resistance among demographic groups. AIDS 30:1439–1445CrossRefPubMedGoogle Scholar
  15. 15.
    Sungkanuparph S, Oyomopito R, Sirivichayakul S, Sirisanthana T, Li PC, Kantipong P, Lee CK, Kamarulzaman A, Messerschmidt L, Law MG, Phanuphak P (2011) HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clin Infect Dis 52:1053–1057CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • Yufan Xu
    • 1
  • Xiaorong Peng
    • 1
  • Xiuming Peng
    • 1
  • Shujing Ji
    • 1
  • Bin Chen
    • 1
  • Liyan Wang
    • 1
  • Xiangyun Lu
    • 1
  • Tiansheng Xie
    • 1
  • Tao Sun
    • 1
  • Hui Wang
    • 2
  • Nanping Wu
    • 1
  1. 1.State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina
  2. 2.The Third People’s Hospital of ShenzhenShenzhenChina

Personalised recommendations